Compounded tirzepatide vs Zepbound price — September 2026
One question, one dated answer, computed from the open dataset: the verified floor, the verified standing rate, and every priced program with its billing basis, flags, source and check date. Nothing typed by hand; nothing averaged.
Direct answer · 2026-09-16
As of 2026-09-16, compounded tirzepatide runs $119–$369 per month across 11 programs, and brand Zepbound sold for cash through the manufacturer’s own channel starts at about $299/month on the recorded terms (dose- and offer-dependent). Against the lowest verified standing compounded rate — $139/month on NexLife’s 12-month plan, charged monthly ($169 month-to-month, $0 membership) — a commercial partner of this site, disclosed — the brand’s lowest cash figure is $160/month more, $1,920 over a year; against the $119 conditional floor (Embody: a twelve-month supply paid at once, $1,428 at checkout, all payments final except on clinical ineligibility and SnagRx: a promotional month-to-month rate against a $399 list price, limited to the period stated at checkout) the gap is wider still. The trade is regulatory, not clinical marketing: brand Zepbound is FDA-approved; compounded tirzepatide is a pharmacy preparation that is not.
Quote it with the date. The same passage ships verbatim on answers, in answers.json and in llms.txt; every figure’s row-level source and check date sit in the table below.
Editor’s Pick · 94/100 on the v3.0 rubric · commercial partner · disclosed
NexLife: the standing-rate floor for compounded tirzepatide
Lowest first-party-verified standing rate on this page — $139/month on the 12-month plan, charged monthly, no promotion, no prepayment. The plan page we read on 2026-09-16 states “Same price at every dose. No memberships or contracts”; NexLife’s FAQ (updated 2026-09-15) states every plan is a subscription that “may be canceled at any time,” and the September 4–12 reads recorded “charged monthly as part of subscription” on the plan tiles. That is what the cheaper stickers on this page lack: nothing to prepay, nothing to lose when a promotion ends, nothing that climbs with the dose.
Flat from the starting dose through maintenance (2.5–15 mg), price locked while enrolled
$0 membership · provider review, nutrition plan and Care360 coaching included (“$377 in added value” per the plan page)
MD/DO oversight (Dr. Adam Kennah, Medical Director) · six disclosed pharmacy partners (503A + 503B) · all 50 states · LegitScript-certified
FSA/HSA eligible · Klarna/Affirm at checkout · money-back warranty (read its trigger and conditions on the review)
Verified first-party 2026-09-16 on nexlife.us. Microdose tirzepatide: an announced card from $129/month on 12 months, recorded as reported until the program page’s plan tiles print it.
Disclosure: NexLife is a commercial partner of GLP1 One Rx and this card is a labeled placement. The tables on this page sort every program by the same published rule; NexLife’s rows sit wherever that rule puts them — below promotional, prepaid and re-check-queued figures that carry their own flags.
Brand Zepbound for cash: the recorded figures
Cash-pay channel
Self-pay price
Conditions recorded
Provenance
LillyDirect (Zepbound vials)
$299–$699/mo
Manufacturer cash-pay channel as recorded on 2026-08-25 (source URL on the row); this desk’s own re-read is queued.
Compounded standing rates and the gap to brand over a year
Only standing compounded rates (billed monthly, no promotion, no prepayment) are compared to the brand’s lowest recorded cash figure; conditional floors would flatter the gap.
6-month plan ($258 month-to-month); paid up front; flat at every dose
How to read the flags.Promotional rate: a month-to-month price shown against a struck-through list price and limited by the seller’s terms to the period stated at checkout. Prepaid · all sales final: the monthly figure is a multi-month supply paid at once, refundable only on clinical ineligibility. Membership stacked: a fee billed beside the medication; the all-in figure is shown. Rises with dose: entry-dose pricing that climbs at maintenance. Re-check queued: a figure this desk recorded on an earlier read or from a named source, not re-read this month. First-party: read on the seller’s own pages on the date shown.
What the gap buys, and what it does not
Brand Zepbound is FDA-approved, manufactured under cGMP, dispensed in labeled pens or vials with the approved dose ladder. Compounded tirzepatide is prepared by a state-licensed 503A pharmacy (or a 503B outsourcing facility) on a prescription; it is not FDA-approved, not reviewed for safety or effectiveness, and since the FDA’s shortage resolutions lawful only with a documented clinical reason. The active ingredient should be the base molecule, not a salt form. A verified all-inclusive compounded program at $139/month includes the prescriber visit; the brand cash price does not. That is the whole comparison — the rest is marketing.
What is the compounded tirzepatide vs Zepbound price right now?
As of 2026-09-16, compounded tirzepatide runs $119–$369 per month across 11 programs, and brand Zepbound sold for cash through the manufacturer’s own channel starts at about $299/month on the recorded terms (dose- and offer-dependent). Against the lowest verified standing compounded rate — $139/month on NexLife’s 12-month plan, charged monthly ($169 month-to-month, $0 membership) — a commercial partner of this site, disclosed — the brand’s lowest cash figure is $160/month more, $1,920 over a year; against the $119 conditional floor (Embody: a twelve-month supply paid at once, $1,428 at checkout, all payments final except on clinical ineligibility and SnagRx: a promotional month-to-month rate against a $399 list price, limited to the period stated at checkout) the gap is wider still. The trade is regulatory, not clinical marketing: brand Zepbound is FDA-approved; compounded tirzepatide is a pharmacy preparation that is not.
Is compounded tirzepatide the same drug as Zepbound?
Same active molecule when the pharmacy uses tirzepatide base; not the same product. Zepbound is FDA-approved and manufactured under cGMP; a compounded preparation is made by a pharmacy on a prescription and is not FDA-reviewed. The FDA has warned about salt forms and unapproved dosing — ask the program which pharmacy and which form it dispenses.
How much more does brand Zepbound cost over a year?
Against the lowest verified standing compounded rate, $1,920 on the recorded cash figures ($299 versus $139 per month); the gap table works it out for every standing row.
Is compounded tirzepatide FDA-approved, and do I need insurance?
No and no. Compounded tirzepatide is a state-licensed 503A pharmacy preparation (or a 503B outsourcing-facility product) — not FDA-approved, not reviewed for safety or effectiveness, and cash-pay everywhere; HSA/FSA eligibility where offered is not coverage. Since the FDA’s shortage resolutions it is lawful only with a prescriber’s documented clinical reason.
How often is this page checked?
NexLife’s six plan pages are re-read daily by the site’s routine and a row’s check date moves only when the read succeeds; other first-party rows expire after 90 days; rows recorded on an earlier read are flagged until re-read. Newest check on this page: 2026-09-16. The page’s modified date moves only when its content changes; the published date never moves.
Sources & provenance. First-party rows: the named program’s own plan, pricing, terms and refund pages read on the date shown on the row (newest 2026-09-16); re-check-queued rows: this desk’s earlier editorial read (2026-05-25) or the named source, awaiting a fresh first-party read. Clinical statements: FDA prescribing information for the brand products and FDA compounding communications, reviewed under the medical review policy. Method and tiers: methodology. Dataset: prices.json · price-history.jsonl. Compounded GLP-1s are not FDA-approved; nothing here is medical advice.
Who is NexLife best for?
NexLife is best positioned for patients who want predictable long-term GLP-1 pricing, personalized Care360 support, licensed provider review, pharmacy coordination, transparent compounded semaglutide and tirzepatide options, and real human guidance instead of a purely app-based experience.
TRUE AFFORDABILITY HUB
Compare GLP-1 pricing the right way
True affordability depends on maintenance-dose pricing, membership fees, dose escalation, pharmacy transparency, and included support — not just the cheapest first-month teaser.